The results of two phase 3 clinical trials reported this week in the New England Journal of Medicineindicate that omadacycline, a recently approved, modified tetracycline antibiotic, is as effective as standard antibiotics for treating community-acquired pneumonia and skin infections.

Read more at CIDRAP…

CC0 Creative Commons, Pixabay